Rockwell Medical (RMTI) Rating Reiterated by Ifs Securities
Rockwell Medical (NASDAQ:RMTI)‘s stock had its “outperform” rating restated by analysts at Ifs Securities in a research report issued to clients and investors on Friday, The Fly reports. They presently have a $11.00 price target on the stock. Ifs Securities’ price objective suggests a potential upside of 159.43% from the stock’s current price.
Other equities analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Rockwell Medical from a “sell” rating to a “buy” rating and set a $4.75 target price on the stock in a report on Wednesday, July 11th. ValuEngine raised shares of Rockwell Medical from a “hold” rating to a “buy” rating in a report on Tuesday, September 4th.
Shares of NASDAQ:RMTI opened at $4.24 on Friday. Rockwell Medical has a one year low of $3.62 and a one year high of $7.40.
Hedge funds have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. grew its holdings in shares of Rockwell Medical by 21.9% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 95,900 shares of the company’s stock valued at $500,000 after purchasing an additional 17,200 shares during the last quarter. Raymond James & Associates boosted its position in Rockwell Medical by 59.0% during the 2nd quarter. Raymond James & Associates now owns 128,276 shares of the company’s stock valued at $632,000 after buying an additional 47,600 shares during the period. Finally, BlackRock Inc. boosted its position in Rockwell Medical by 4.8% during the 2nd quarter. BlackRock Inc. now owns 3,195,923 shares of the company’s stock valued at $15,756,000 after buying an additional 147,384 shares during the period. 22.20% of the stock is currently owned by institutional investors.
About Rockwell Medical
Rockwell Medical, Inc operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company's lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment.
Recommended Story: What is the S&P 500 Index?
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.